Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
复制标题
开发和验证简化版的扩展前列腺癌指数综合仪器，用于测量前列腺癌幸存者的健康相关生活质量。
DOI：
10.1016/j.urology.2010.01.027
复制
发表时间：
2010-11
期刊：
影响因子：
2.1
通讯作者：
Sanda MG
中科院分区：
文献类型：
--
作者：
Szymanski KM;Wei JT;Dunn RL;Sanda MG
Widespread implementation of HRQOL measurement in prostate cancer practice and research requires concise instruments. Having 50 questions, the full-length Expanded Prostate cancer Index Composite (EPIC) is cumbersome to administer outside of studies focusing exclusively on HRQOL. To facilitate HRQOL measurement in a broad range of prostate cancer research and practice settings, we developed and validated an abbreviated version of EPIC. 50 questions that comprise the full-length EPIC-50 were evaluated to identify items suitable for elimination while retaining ability to measure the 5 prostate cancer-specific HRQOL domains of EPIC-50. The resulting abbreviated version (EPIC-26) was validated using question responses from 252 subjects who had brachytherapy, external radiotherapy or prostatectomy for prostate cancer. EPIC-26 internal consistency was measured by Cronbach's alpha coefficient and reliability by test-retest correlation. Based on high item-scale correlations, clinically relevant content, and preservation of domain psychometrics, 26 items were retained in EPIC-26 from 50 questions in the full length EPIC-50. High correlation was observed between EPIC-50 and EPIC-26 versions of urinary incontinence, urinary irritation/obstruction, bowel, sexual and vitality/hormonal domain scores (all r ≥0.96). Correlations between different domains were low, confirming that EPIC-26 retains the ability to discern 5 distinct HRQOL domains. Internal consistency and test-retest reliability for EPIC-26 (Cronbach's alpha ≥0.70 and r ≥ 0.69, respectively for all 5 HRQOL domains) support its validity. EPIC-26 is a brief, valid and reliable subjective measure of health quality among prostate cancer patients and suitable for measuring HRQOL among patients undergoing treatment for early stage prostate cancer.
登录
查看更多内容
影响因子：
2.1
作者：
Esper, P;Mo, F;Pienta, KJ
通讯作者：
Pienta, KJ
影响因子：
120.7
作者：
LITWIN, MS;HAYS, RD;BROOK, RH
通讯作者：
BROOK, RH
影响因子：
23.4
作者：
Schroeck, Florian R.;Krupski, Tracey L.;Moul, Judd W.
通讯作者：
Moul, Judd W.
影响因子：
2.6
作者：
Hashine, Katsuyoshi;Miura, Noriyoshi;Kataoka, Masaaki
通讯作者：
Kataoka, Masaaki
影响因子：
6.6
作者：
SLOB, AK;BLOM, JHM;TENBOSCH, JJV
通讯作者：
TENBOSCH, JJV